Company Interview / INOVIQ targeting breast cancer breakthrough

Dr Leearne Hinch CEO of INOVIQ (ASX:IIQ) shares progress in their exosome therapeutic program for breast cancer. They've achieved in vitro proof of concept, showing their natural killer cell-derived exosome can target and kill cancer cells. The next step involves advancing in vivo studies with animal models.

Leearne explains that exosomes are small packages from cells, inheriting cancer-killing and targeting properties from natural killer cells. They're advancing towards clinical trials by optimizing exosome potency and targeting cancers without harming healthy cells. A parallel program investigates T lymphocyte-derived exosomes.

INOVIQ's (ASX:IIQ) diagnostics program runs alongside therapeutics, focusing on early detection and monitoring of breast and ovarian cancers. Leearne mentions the company has $10 million to fund ongoing developments and commercial efforts with partners like Promega. The upcoming in vivo milestone is crucial for progress.